The new Chonburi plant is designed to supply battery packs directly to locally assembled Aion Y Plus electric vehicles. Initial manufacturing capabilities for the project's first phase are planned at 7,000 units annually, with an intended expansion that could eventually push capacity to 20,000 packs per year. This development complements GAC's active vehicle manufacturing lines by establishing a comprehensive local supply network outside of China.
The facility plays a strategic role in shortening delivery timelines for customers within…: The facility plays a strategic role in shortening delivery timelines for customers within the Thai automotive market.
Establishing manufacturing hubs outside of China supports the automaker's long-term busin…: Establishing manufacturing hubs outside of China supports the automaker's long-term business expansion throughout Southeast Asia.
Sources checked by our analysis pipeline: 1
BEIJING, Nov 3 : Guangzhou Automobile Group said on Tuesday its first overseas self-developed battery pack plant started production in Thailand on October 29, marking a key step in localising its EV supply chain overseas.
• The facility will complement GAC's existing vehicle manufacturing operations in Thailand, allowing the automaker to localise both vehicle assembly and core battery components, according to a company statement
• The plant, operated by battery unit INPOW, is located in Thailand's Chonburi province and will supply battery packs for locally produced Aion Y Plus electric vehicles
• Phase one of the project has a planned annual capacity of 7,000 battery packs, while a second phase could raise capacity to 20,000 packs per year, the company said
• GAC said the plant would help shorten delivery times, improve supply-chain security in Thailand and support its expansion in the wider Southeast Asian market
The pharmaceutical giant is updating its multi-year outlook after delivering financial results that exceeded expectations for the recent quarter. Robust commercial demand for critical oncology treatments and the blood thinner Eliquis fueled this upward trajectory. Consequently, the company is expressing stronger confidence in its operational targets leading into 2026.
The fast-food chain is grappling with deeper customer cutbacks across its locations following recent health concerns. Financial results show the resulting downturn has surpassed internal and industry projections, complicating short-term revenue expectations. Leadership now faces the challenge of stabilizing foot traffic to curb ongoing losses.